drugset / Trial / NCT01862835

Impact of Estradiol Addback

NCT01862835

Phase 1 Completed 43 enrolled Mayo Clinic
RandomizedCrossoverTriple-blindBasic science

Summary

Repletion of testosterone (T) in older men drives Growth Hormone secretion after its aromatization to estradiol (E2) by potentiating endogenous GH drive.

Timeline

Start
2013-05
Primary completion
2016-09-30
Completion
2018-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Anastrozole Other / unclassified 2 mg Oral
Subject Estradiol Other / unclassified 0.05 mg Other
Subject Testosterone Small molecule 100 mg Intramuscular
Background Degarelix Other / unclassified 80 mg Subcutaneous

Indications

No indication recorded.